Fármacos de la enfermedad de ojo seco actualmente en evaluación de ensayos clínicos

Dry eye syndrome is a common disorder provoking changes in tear quantity and composition being the most common ophthalmic manifestation of systemic inflammatory diseases. Untreated dry eye could cause increased risk of ocular infection, corneal ulcer and blindness. Only a few drugs are authorized so far for the treatment of dry eye disease and the possibilities of evolution in this sector are immense. Accordingly, the future tendency is towards the development of drugs to control the inflammation or stimulate the mucin and tear secretion. A significant number of new potential solutions are under development or placed in the pharmaceutical pipeline, promising better results and lesser side effects, but still leaving unattended the main causes of the disease. In this article, we review the corresponding literature, recent clinical trials data and patents concerning future pharmaceutical compounds for dry eye disease treatment, presenting the new strategic movements of the pharmaceutical industry.